Last reviewed · How we verify
Intramuscular methylprednisolone acetate
Methylprednisolone acetate is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting inflammatory mediators and immune cell activation.
Methylprednisolone acetate is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting inflammatory mediators and immune cell activation. Used for Inflammatory and autoimmune conditions responsive to corticosteroid therapy, Rheumatoid arthritis, Lupus and other connective tissue diseases.
At a glance
| Generic name | Intramuscular methylprednisolone acetate |
|---|---|
| Also known as | steroid |
| Sponsor | Montefiore Medical Center |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / General anti-inflammatory |
| Phase | Phase 3 |
Mechanism of action
Methylprednisolone acetate binds to glucocorticoid receptors in the cytoplasm, translocating to the nucleus to modulate gene expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. This results in decreased recruitment and activation of immune cells, reduced vascular permeability, and suppression of both humoral and cell-mediated immune responses. The acetate ester formulation provides sustained release when administered intramuscularly.
Approved indications
- Inflammatory and autoimmune conditions responsive to corticosteroid therapy
- Rheumatoid arthritis
- Lupus and other connective tissue diseases
- Severe allergic reactions
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes
- Immunosuppression / increased infection risk
- Osteoporosis with chronic use
- Injection site reactions
Key clinical trials
- Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares (PHASE4)
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (PHASE2)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children (PHASE3)
- The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis (PHASE3)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD) (PHASE2)
- Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome (PHASE2)
- Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: